Customer Demand Communication and Project Design
Initial consultation clarifies objectives; we then collaboratively design a tailored project plan outlining approach, timelines, and deliverables.
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.
At Creative Biolabs, with over two decades of leadership in biotechnology, we offer unparalleled RNA interference (RNAi) based anti-Monkeypox drug discovery solutions. Our strength lies in translating complex science into actionable strategies, empowering our clients to rapidly develop precise and effective antiviral therapeutics against emerging threats like Monkeypox.
Monkeypox virus (MPXV) is a large, enveloped double-stranded DNA virus within the Orthopoxvirus genus, closely related to the variola virus. It causes monkeypox, a zoonotic disease characterized by fever, headache, muscle aches, swollen lymph nodes, and a distinctive rash that progresses through several stages. The pathogenicity of MPXV highlights the need for novel and specific antiviral interventions to manage outbreaks, prevent severe disease, and address potential drug resistance, ensuring global health security.
RNAi is a fundamental biological process that regulates gene expression by silencing specific messenger RNA (mRNA) molecules. This natural cellular defense mechanism, harnessed as a therapeutic tool, involves small RNA molecules (like siRNAs or miRNAs) guiding the RNA-induced silencing complex (RISC) to complementary mRNA sequences. Upon binding, RISC either cleaves the target mRNA or inhibits its translation, effectively preventing the production of the corresponding protein. This precise mechanism offers an innovative pathway for targeted antiviral drug development.
Fig.1 An overview of biogenesis and intracellular processing of RNAi inducers.1
Creative Biolabs provides comprehensive, cutting-edge RNAi-based drug discovery solutions for anti-Monkeypox therapeutics, guiding your project from conceptualization to preclinical validation. Our integrated services leverage deep scientific expertise and advanced platforms to deliver highly specific, potent antiviral candidates.
MicroRNAs (miRNAs) are small, non-coding RNAs that regulate gene expression by binding to target mRNAs, leading to repression or degradation. In viral infections, miRNAs modulate host-virus interactions, making them attractive targets or agents for anti-Monkeypox strategies. Manipulating host or introducing synthetic miRNAs can influence viral replication or host antiviral responses.
We identify and validate host miRNAs dysregulated during MPXV infection or viral miRNAs essential for replication through bioinformatic analysis and in vitro screening.
Our experts design and synthesize high-quality miRNA mimics to enhance beneficial host responses or inhibitors to block pro-viral host miRNAs, ensuring specificity and stability.
We evaluate miRNA-based candidates' antiviral efficacy in in vitro MPXV-infected cell models, assessing viral load reduction and cytopathic effects.
We develop and optimize advanced delivery systems, including LNPs and viral vectors, for efficient, targeted in vivo delivery to relevant tissues in animal models.
Comprehensive in vivo studies assess ADME profiles and biological activity of miRNA candidates in animal models for optimal therapeutic potential.
Short interfering RNAs (siRNAs) are double-stranded RNA molecules (20-25 bp) that trigger the RNAi pathway by directing RISC to cleave complementary mRNA. For anti-Monkeypox therapy, siRNAs directly target essential viral genes, silencing their expression and disrupting the viral life cycle with high precision.
We pinpoint highly conserved, essential MPXV genes (e.g., DNA polymerase, helicase, envelope proteins) critical for replication and pathogenesis using bioinformatics and functional genomics.
Our team designs potent, specific siRNA sequences against identified MPXV targets, employing algorithms to minimize off-target effects and maximize silencing efficiency.
We conduct robust in vitro screening of siRNA libraries in MPXV-infected cell lines to identify lead candidates with significant antiviral activity, measuring viral replication and protein expression.
We develop and optimize cutting-edge delivery platforms, particularly LNP formulations, for efficient, safe systemic or localized in vivo delivery of siRNAs to target cells.
Rigorous in vivo studies in animal models evaluate antiviral efficacy, pharmacokinetics, pharmacodynamics, and safety profiles of lead siRNA candidates, paving the way for clinical translation.
Short hairpin RNAs (shRNAs) are synthetic RNA molecules with a hairpin turn, expressed from viral vectors (e.g., lentivirus, AAV) within cells. Processed into siRNAs, they trigger the RNAi pathway, allowing stable, long-term gene silencing suitable for sustained therapeutic effects against persistent viral threats like Monkeypox.
We design shRNA constructs targeting essential MPXV genes or host factors, optimizing their expression for sustained gene silencing in various cell types.
Our expertise includes designing and producing high-titer, safe, and efficient viral vectors (e.g., lentiviral or adeno-associated viral vectors) for stable shRNA delivery and expression.
We perform in vitro transduction experiments to deliver shRNAs into target cells, validating gene silencing efficiency and antiviral activity against MPXV using qPCR, Western blot, and viral titer assays.
We assess in vivo delivery efficiency and sustained shRNA expression via optimized viral vectors in animal models, ensuring therapeutic molecule reaches target tissues effectively.
Comprehensive in vivo studies evaluate long-term antiviral efficacy, durability of gene silencing, and potential toxicological profiles of shRNA-based therapies, crucial for regulatory submission.
Initial consultation clarifies objectives; we then collaboratively design a tailored project plan outlining approach, timelines, and deliverables.
Upon agreement, a detailed service contract is finalized, defining scope, IP, and payment terms. This formalizes our partnership, enabling prompt experimental initiation.
Experienced scientists meticulously execute protocols in state-of-the-art facilities. Rigorous quality control ensures data integrity and reliability.
Our expert team analyzes all experimental data, compiling professional, accessible reports with raw data, analyzed results, and actionable insights.
Final reports and data are securely delivered. We commit to your success, offering ongoing follow-up consultations and technical support for subsequent research
Click the button to contact us for service details and a custom quote.
The mechanism of action of RNAi in combating MPXV centers on its ability to precisely silence essential viral gene expression. When a synthetic siRNA or an endogenously processed shRNA is introduced into an MPXV-infected cell, it is incorporated into the RISC. This RISC complex, guided by the complementary sequence of the small RNA, then locates and binds to specific mRNA transcripts produced by the MPXV. Upon recognition, the RISC complex cleaves the viral mRNA, or inhibits its translation, thereby preventing the synthesis of critical viral proteins necessary for replication, assembly, and pathogenesis. This targeted degradation or inhibition effectively disarms the virus, halting its life cycle and reducing viral load without significantly impacting host cellular functions.
Precision Targeting
Our RNAi solutions are engineered for unparalleled specificity, directly targeting conserved and essential MPXV genes to minimize off-target effects on host cells, ensuring enhanced safety.
Comprehensive Pipeline
Creative Biolabs offers an end-to-end service, from initial target identification and intelligent RNAi design to advanced delivery system development and rigorous preclinical validation.
Accelerated Discovery
Leverage our optimized platforms and streamlined processes to significantly reduce your anti-Monkeypox drug discovery timelines, bringing promising candidates to fruition faster.
Robust Validation
We employ meticulous in vitro and in vivo validation strategies, ensuring the potency, specificity, and efficacy of lead candidates, thereby mitigating development risks.
Expert Guidance
Benefit from our team's deep scientific acumen and decades of experience in nucleic acid therapeutics and antiviral drug discovery, providing invaluable insights and support.
RNAi therapeutics are designed with sequences highly complementary to specific Monkeypox viral messenger RNAs. This precise sequence matching ensures that the RISC primarily recognizes and degrades only the viral transcripts, leaving host cellular mRNAs largely unaffected. Our rigorous design algorithms and validation processes further enhance this specificity.
A primary challenge involves efficient and safe delivery of RNAi molecules to target cells in vivo, as naked RNA is prone to degradation and poor cellular uptake. Creative Biolabs addresses this through advanced lipid nanoparticle (LNP) formulations and optimized viral vectors, which encapsulate and protect the RNAi molecules, facilitating their targeted delivery to infected cells or tissues.
Yes, RNAi offers a strong advantage against resistance. By targeting highly conserved regions of essential viral genes, or by simultaneously targeting multiple genes, it becomes significantly more difficult for the virus to develop resistance through single point mutations. Our strategies focus on identifying such robust targets.
The suitability depends on the desired duration of silencing and delivery method. siRNAs offer transient but potent silencing, miRNAs can modulate host pathways, and shRNAs provide stable, long-term silencing via viral vectors. Creative Biolabs' experts guide clients through a comprehensive assessment of their project goals, target characteristics, and delivery considerations to recommend the optimal RNAi modality.
We utilize a range of validated preclinical models to assess efficacy. This includes in vitro cell culture models infected with MPXV to evaluate viral replication inhibition and cytopathic effects. For in vivo studies, we employ established animal models that mimic Monkeypox disease progression, allowing for comprehensive evaluation of antiviral activity, pharmacokinetics, and safety.
Quality and reproducibility are paramount at Creative Biolabs. We adhere to stringent quality control measures at every stage, from raw material sourcing and RNAi synthesis to experimental execution and data analysis. Our processes are standardized, and all experiments are conducted by highly trained scientists using validated protocols and state-of-the-art equipment, ensuring reliable and reproducible results.
As an industry-leading service provider, Creative Biolabs is committed to offering a full range of monkeypox products and specialized solutions equipped with state-of-the-art high-throughput screening, artificial intelligence, in vitro and in vivo platforms. Our experienced team helps you design customized RNAi-based anti-monkeypox agent discovery programs. Please do not hesitate to contact us to learn more details.
Reference
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.